

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

STA Equality impact assessment – Scoping

Bimekizumab for treating axial spondyloarthritis

Batch 83

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company highlighted that the condition affects women more frequently and that women also typically experience disease which responds less well to some treatments.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues about differences in the prevalence or incidence of a condition cannot be addressed in a technology evaluation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not required.

Approved by Associate Director (name): Richard Diaz
Date: 28 April 2023